Loading company…
Weiyuan provides synthetic biology services and develops biologics and chiral chemicals.
Weiyuan uses engineered strain screening and AI enzyme evolution technologies to provide enzyme evolution, peptide industrialization, functional protein customization, and nucleotide modification services. Its products include active biologics and chiral chemicals. Based in Hangzhou, China, the company was established in 2023 and raised CNY 300 million in Series A funding from He'nan Investment Group in March 2026.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in